Jun 30, 2026 7:00am EDT Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Jun 16, 2026 7:00am EDT Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Jun 15, 2026 7:02am EDT Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Jun 02, 2026 7:02am EDT Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 04, 2026 7:01am EDT Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Apr 20, 2026 7:01am EDT Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 01, 2026 7:01am EDT Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Feb 17, 2026 7:01am EST Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 13, 2026 7:01am EST Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Dec 02, 2025 7:00am EST Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
